Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection
| Autor: | Xiao-Ping Chen, Yin Xiao Du |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
viruses
Pharmacology Favipiravir 030226 pharmacology & pharmacy Antiviral Agents Virus 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Pharmacokinetics Medicine Animals Humans Pharmacology (medical) Drug Interactions Acetaminophen Clinical Trials as Topic business.industry Ribavirin Lopinavir Chloroquine Phosphate Amides COVID-19 Drug Treatment Clinical trial chemistry 030220 oncology & carcinogenesis Pyrazines Ritonavir business Coronavirus Infections medicine.drug |
| Zdroj: | Clinical Pharmacology & Therapeutics |
| ISSN: | 1532-6535 |
| Popis: | An outbreak of 2019-nCoV infection has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID-2019. In addition to the recommended antiviral drugs, such as interferon-ɑ, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA-dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug-drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID-2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text